Cost-effectiveness of the polypill versus risk assessment for prevention of cardiovascular disease

Heart

Volumn 103, Issue 7, 2017, Pages 491-499

  Ferket, Bart S ^a,b   Hunink, M G Myriam ^b,c   Khanji, Mohammed ^d   Agarwal, Isha ^c   Fleischmann, Kirsten E ^e   Petersen, Steffen E ^d  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; HYDROCHLOROTHIAZIDE; LOSARTAN; SIMVASTATIN; ANTIHYPERTENSIVE AGENT; DRUG COMBINATION; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TABLET;

ADULT; AGE; AGED; ARTICLE; BIOBANK; CARDIOVASCULAR DISEASE; COST EFFECTIVENESS ANALYSIS; DEATH; DIABETES MELLITUS; DRUG COST; DRUG USE; FEMALE; HUMAN; MALE; POLYPHARMACY; PRESCRIPTION; QUALITY OF LIFE; RISK ASSESSMENT; SIMULATION; SURVIVAL RATE; CARDIOVASCULAR DISEASES; COMPARATIVE STUDY; COMPLICATION; COMPUTER SIMULATION; COST BENEFIT ANALYSIS; DRUG COMBINATION; DYSLIPIDEMIAS; ECONOMIC MODEL; ECONOMICS; HYPERTENSION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PRIMARY PREVENTION; PROCEDURES; QUALITY ADJUSTED LIFE YEAR; RISK FACTOR; TABLET; TIME FACTOR; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DRUG COMBINATIONS; DRUG COSTS; DYSLIPIDEMIAS; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; LOSARTAN; MALE; MIDDLE AGED; MODELS, ECONOMIC; PRIMARY PREVENTION; QUALITY-ADJUSTED LIFE YEARS; RISK ASSESSMENT; RISK FACTORS; SIMVASTATIN; TABLETS; TIME FACTORS; TREATMENT OUTCOME;

EID: 85016931272     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2016-310529     Document Type: Article

References (33)

1. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63(25 Pt B):2889-934.
2. National Institute for Health and Care Excellence. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. Issued July 2014. London: National Institute for Health and Care Excellence, 2014.
3. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003;326:1419.
4. Polypill.com. https://www.polypill.com/ (accessed 15 Jun 2016).
5. Wald DS, Morris JK, Wald NJ. Randomized polypill crossover trial in people aged 50 and over. PLoS One 2012;7:e41297.
6. Pandya A, Sy S, Cho S, et al. Cost-effectiveness of 10-year risk thresholds for initiation of statin therapy for primary prevention of cardiovascular disease. JAMA 2015;314:142-50.
7. Sundström J, Arima H, Woodward M, et al., Blood Pressure Lowering Treatment Trialists' Collaboration. Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet 2014;384:591-8.
8. Wright JT Jr, Williamson JD, Whelton PK, et al., SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015;373:2103-16.
9. Elley CR, Gupta AK, Webster R, et al. The efficacy and tolerability of 'polypills': meta-analysis of randomised controlled trials. PLoS One 2012;7:e52145.
10. Hippisley-Cox J, Coupland C, Robson J, et al. Derivation, validation, and evaluation of a new QRISK model to estimate lifetime risk of cardiovascular disease: cohort study using QResearch database. BMJ 2010;341:c6624.
11. Hippisley-Cox J, Coupland C, Robson J, et al. Predicting risk of type 2 diabetes in England and Wales: prospective derivation and validation of QDScore. BMJ 2009;338:b880.
12. Sudlow C, Gallacher J, Allen N, et al. UK Biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med 2015;12:e1001779.
13. Office for National Statistics. National Life Tables, 2010-2012. http://www.ons.gov.uk/ons/rel/lifetables/national-life-tables/2010-2012/index.html (accessed 15 Jun 2016).
14. National Institute for Health and Care Excellence. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. Updated in 2010. London: National Institute for Health and Care Excellence, 2008.
15. NHS Health Check. http://www.healthcheck.nhs.uk/ (accessed 15 Jun 2016).
16. National Institute for Health and Care Excellence. Type 2 diabetes. The management of type 2 diabetes. Updated in 2014. London: National Institute for Health and Care Excellence, 2009.
17. National Institute for Health and Clinical Excellence. Hypertension: the clinical management of primary prevention in adults. London: National Institute for Health and Clinical Excellence, 2011.
18. Rubinstein A, Garcia Martí S, Souto A, et al. Generalized cost-effectiveness analysis of a package of interventions to reduce cardiovascular disease in Buenos Aires, Argentina. Cost Eff Resour Alloc 2009;7:10.
19. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338:b1665.
20. Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013;(1):CD004816.
21. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010;375:735-42.
22. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007;369:201-7.
23. Fontana M, Asaria P, Moraldo M, et al. Patient-accessible tool for shared decision making in cardiovascular primary prevention: balancing longevity benefits against medication disutility. Circulation 2014;129:2539-46.
24. Hutchins R, Viera AJ, Sheridan SL, et al. Quantifying the utility of taking pills for cardiovascular prevention. Circ Cardiovasc Qual Outcomes 2015;8:155-63.
25. National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013. Process and methods guides. National Institute for Health and Care Excellence, 2013.
26. van Gils PF, Over EA, Hamberg-van Reenen HH, et al. The polypill in the primary prevention of cardiovascular disease: cost-effectiveness in the Dutch population. BMJ Open 2011;1:e000363.
27. de Cates AN, Farr MR, Wright N, et al. Fixed-dose combination therapy for the prevention of cardiovascular disease. Cochrane Database Syst Rev 2014;(4):CD009868.
28. Petretta M, Costanzo P, Perrone-Filardi P, et al. Impact of gender in primary prevention of coronary heart disease with statin therapy: a meta-analysis. Int J Cardiol 2010;138:25-31.
29. Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 2009;338:b2376.
30. Kostis WJ, Cheng JQ, Dobrzynski JM, et al. Meta-analysis of statin effects in women versus men. J Am Coll Cardiol 2012;59:572-82.
31. Pencina MJ, Navar-Boggan AM, D'Agostino RB Sr, et al. Application of new cholesterol guidelines to a population-based sample. N Engl J Med 2014;370:1422-31.
32. Ioannidis JP. More than a billion people taking statins?: Potential implications of the new cardiovascular guidelines. JAMA 2014;311:463-4.
33. Wise J. Open letter raises concerns about NICE guidance on statins. BMJ 2014;348:g3937.